SCHEMBL3881340

SCHEMBL3881340

N#Cc1cccc(-c2ccc(O)nc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 2/20 0.53
XDH P47989 1/20 0.51
SLC22A12 Q96S37 1/20 0.51
EGLN1 Q9GZT9 2/20 0.48
MAP4K4 O95819 1/20 0.48
GABRG2 P18507 5/20 0.48
GABRB3 P28472 5/20 0.48
GABRA5 P31644 5/20 0.48
GABRA3 P34903 5/20 0.48
GABRA1 P14867 1/20 0.48
PLG P00747 1/20 0.47
PLAU P00749 1/20 0.47
IDO1 P14902 2/20 0.46
NEK1 Q96PY6 1/20 0.46
CYP17A1 P05093 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20646149 0.80 MMP3 (0.57) EGLN1MAP4K4GABRG2GABRB3GABRA5
SCHEMBL6923115 0.80 CLK4 (0.53) CLK4XDHSLC22A12MAP4K4GABRG2
SCHEMBL3266198 0.80 CLK4 (0.53) CLK4MAP4K4GABRG2GABRB3GABRA5
SCHEMBL5562910 0.80 MAP4K4 (0.62) CLK4MAP4K4GABRG2GABRB3GABRA5
SCHEMBL4021783 0.80 CYP11B2 (0.56) CLK4MAP4K4GABRG2GABRB3GABRA5
SCHEMBL15577546 0.79 EGLN1 (0.56) CLK4XDHSLC22A12EGLN1GABRG2
SCHEMBL2154026 0.78 CLK4 (0.65) CLK4XDHSLC22A12MAP4K4GABRG2
SCHEMBL322948 0.77 MMP3 (0.63) CLK4XDHSLC22A12CYP3A4PTPN5
SCHEMBL14224867 0.76 CLK4 (0.49) CLK4EGLN1MAP4K4GABRG2GABRB3
SCHEMBL18223984 0.76 SYK (0.53) CLK4MAP4K4GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
EP-2010485-A1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS Prosidion Limited (GB) 2009-01-07 EP disclosed
WO-2007116230-A1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists GPR119, GPR39, GIPR CLK4 4733/4885XDH 3350/4885SLC22A12 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.